Faron Pharmaceuticals Oy Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	7.61	6.93	9.05	7.51	9.88	Upgrade
Research & Development	12.66	11.74	19.52	20.71	17.36	Upgrade
Other Operating Expenses	-	-	-	-0.8	-6.14	Upgrade
Operating Expenses	20.27	18.67	28.57	27.43	21.11	Upgrade
Operating Income	-20.27	-18.67	-28.57	-27.43	-21.11	Upgrade
Interest Expense	-1.27	-3.94	-2.13	-1.37	-0.22	Upgrade
Interest & Investment Income	0.06	0.09	0.23	0.01	0	Upgrade
Currency Exchange Gain (Loss)	-0.11	0.07	0.01	0.04	0.16	Upgrade
Other Non Operating Income (Expenses)	-6.97	-3.46	-0.49	0.01	-0.02	Upgrade
EBT Excluding Unusual Items	-28.56	-25.92	-30.94	-28.73	-21.18	Upgrade
Other Unusual Items	1.31	-	-	-	-	Upgrade
Pretax Income	-27.26	-25.92	-30.94	-28.73	-21.18	Upgrade
Income Tax Expense	0	0.01	-	-	0.02	Upgrade
Net Income	-27.26	-25.92	-30.94	-28.73	-21.19	Upgrade
Net Income to Common	-27.26	-25.92	-30.94	-28.73	-21.19	Upgrade
Shares Outstanding (Basic)	112	89	65	55	51	Upgrade
Shares Outstanding (Diluted)	112	89	65	55	51	Upgrade
Shares Change (YoY)	26.21%	36.07%	17.79%	8.88%	10.96%	Upgrade
EPS (Basic)	-0.24	-0.29	-0.48	-0.52	-0.42	Upgrade
EPS (Diluted)	-0.24	-0.29	-0.48	-0.52	-0.42	Upgrade
Free Cash Flow	-17.92	-22.31	-23.81	-22.99	-22.23	Upgrade
Free Cash Flow Per Share	-0.16	-0.25	-0.37	-0.42	-0.44	Upgrade
EBITDA	-20.05	-18.47	-28.37	-27.29	-20.97	Upgrade
D&A For EBITDA	0.22	0.2	0.2	0.14	0.14	Upgrade
EBIT	-20.27	-18.67	-28.57	-27.43	-21.11	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.